Continuing clinical trials in the face of the COVID-19 pandemic has posed myriad challenges to an industry some experts have characterized as largely unprepared for a public health emergency. But lessons learned from operating under pandemic conditions may accelerate innovations the industry currently is only toying with, including decentralization of clinical trials and technology-aided remote monitoring.